Calamos Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $433K | Sell |
7,517
-1,112
| -13% | -$63.9K | 0.01% | 321 |
|
|
2026
Q1 | $523K | Buy |
8,629
+1,553
| +22% | +$90.5K | 0.02% | 292 |
|
|
2025
Q4 | $382K | Sell |
7,076
-6
| -0.1% | -$289 | 0.01% | 311 |
|
|
2025
Q3 | $319K | Buy |
7,082
+560
| +9% | +$26.2K | 0.01% | 333 |
|
|
2025
Q2 | $302K | Sell |
6,522
-545
| -8% | -$26.8K | 0.01% | 286 |
|
|
2025
Q1 | $431K | Sell |
7,067
-4,056
| -36% | -$236K | 0.02% | 229 |
|
|
2024
Q4 | $629K | Buy |
11,123
+270
| +2% | +$15.1K | 0.03% | 195 |
|
|
2024
Q3 | $562K | Sell |
10,853
-5,917
| -35% | -$278K | 0.03% | 208 |
|
|
2024
Q2 | $696K | Buy |
16,770
+1,149
| +7% | +$51.4K | 0.04% | 170 |
|
|
2024
Q1 | $847K | Sell |
15,621
-221
| -1% | -$11.3K | 0.05% | 161 |
|
|
2023
Q4 | $813K | Sell |
15,842
-2,804
| -15% | -$147K | 0.05% | 154 |
|
|
2023
Q3 | $1.08M | Sell |
18,646
-104,165
| -85% | -$6.38M | 0.08% | 136 |
|
|
2023
Q2 | $7.85M | Sell |
122,811
-32,212
| -21% | -$2.16M | 0.58% | 45 |
|
|
2023
Q1 | $10.7M | Sell |
155,023
-21,344
| -12% | -$1.51M | 0.84% | 25 |
|
|
2022
Q4 | $12.7M | Buy |
176,367
+1,128
| +0.6% | +$85.1K | 0.99% | 22 |
|
|
2022
Q3 | $12.5M | Buy |
175,239
+5,641
| +3% | +$409K | 1.07% | 20 |
|
|
2022
Q2 | $13.1M | Buy |
169,598
+9,826
| +6% | +$748K | 1.16% | 16 |
|
|
2022
Q1 | $11.7M | Buy |
159,772
+49,156
| +44% | +$3.3M | 0.87% | 25 |
|
|
2021
Q4 | $6.9M | Buy |
110,616
+1,698
| +2% | +$99.6K | 0.5% | 52 |
|
|
2021
Q3 | $6.45M | Buy |
108,918
+40,106
| +58% | +$2.64M | 0.52% | 48 |
|
|
2021
Q2 | $4.6M | Sell |
68,812
-1,576
| -2% | -$103K | 0.36% | 71 |
|
|
2021
Q1 | $4.44M | Buy |
70,388
+1,751
| +3% | +$109K | 0.37% | 72 |
|
|
2020
Q4 | $4.26M | Buy |
68,637
+9,091
| +15% | +$559K | 0.39% | 71 |
|
|
2020
Q3 | $3.59M | Buy |
59,546
+2,360
| +4% | +$142K | 0.41% | 65 |
|
|
2020
Q2 | $3.36M | Buy |
57,186
+1,250
| +2% | +$74.8K | 0.42% | 67 |
|
|
2020
Q1 | $3.12M | Buy |
+55,936
| New | +$3.42M | 0.48% | 55 |
|
|
2018
Q2 | – | Sell |
-9,294
| Closed | -$588K | – | 214 |
|
|
2018
Q1 | $588K | Buy |
+9,294
| New | +$598K | 0.07% | 146 |
|
|
2015
Q2 | – | Sell |
-5,600
| Closed | -$361K | – | 227 |
|
|
2015
Q1 | $361K | Sell |
5,600
-695
| -11% | -$43.5K | 0.09% | 180 |
|
|
2014
Q4 | $372K | Buy |
+6,295
| New | +$355K | 0.11% | 178 |
|
Other funds holding BMY
Calamos Wealth Management's BMY Position: Q2 2026 in Review
Calamos Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 13% in Q2 2026, selling an estimated $63.9K and leaving 7,517 shares worth $433K. The position accounts for 0.01% of the portfolio, ranked #321.
Calamos Wealth Management first reported a position in BMY in Q4 2014 and has held it in 29 quarters since. The position peaked at $13.1M in Q2 2022. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Calamos Wealth Management held 7,517 shares of Bristol-Myers Squibb worth $433K as of Q2 2026.
- Calamos Wealth Management sold 1,112 Bristol-Myers Squibb shares in Q2 2026, an estimated $63.9K.
- Bristol-Myers Squibb made up 0.01% of Calamos Wealth Management's portfolio in Q2 2026, its #321 holding.
- Calamos Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 29 quarters since.
- Calamos Wealth Management's Bristol-Myers Squibb position peaked at $13.1M in Q2 2022.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.